Translation
Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.
Summary of Consolidated Financial Results for the Six Months Ended June 30, 2023 (Based on Japanese GAAP)
August 10, 2023 | |||||
Company name: | D.Western Therapeutics Institute, Inc. | ||||
Stock exchange listing: | Tokyo | ||||
Stock code: | 4576 | URL https://www.dwti.co.jp | |||
Representative: | President and CEO | Yuichi Hidaka | |||
Inquiries: | Director | Sayako Matsubara | TEL 052-218-8785 | ||
Scheduled date to file Quarterly Securities Report: | August 10, 2023 | ||||
Scheduled date to commence dividend payments: | - | ||||
Preparation of supplementary material on quarterly financial results: | Yes | ||||
Holding of quarterly financial results meeting: | Yes | (for analysts and institutional investors) |
(Amounts less than one million yen are rounded down)
1. Consolidated financial results for the six months ended June 30, 2023 (from January 1, 2023 to June 30, 2023)
(1) Consolidated operating results (cumulative) | Percentages indicate year-on-year changes | ||||||||||
Net sales | Operating profit | Ordinary profit | Profit attributable to | ||||||||
owners of parent | |||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | ||||
Six months ended June 30, 2023 | 187 | (10.6) | (258) | - | (254) | - | (247) | - | |||
Six months ended June 30, 2022 | 210 | 4.2 | (132) | - | (118) | - | (110) | - |
Earnings per share | Diluted earnings per share | ||||||||
Yen | Yen | ||||||||
Six months ended June 30, 2023 | (7.89) | - | |||||||
Six months ended June 30, 2022 | (3.76) | - | |||||||
(2) Consolidated financial position | |||||||||
Total assets | Net assets | Equity ratio | |||||||
Millions of yen | Millions of yen | % | |||||||
As of June 30, 2023 | 2,820 | 1,820 | 64.2 | ||||||
As of December 31, 2022 | 2,956 | 1,873 | 62.8 | ||||||
2. Cash dividends | |||||||||
Annual dividends per share | |||||||||
1st quarter-end | 2nd quarter-end | 3rd quarter-end | Fiscal year-end | ||||||
Yen | Yen | Yen | Yen | ||||||
Year ended December 31, 2022 | - | 0.00 | - | 0.00 | |||||
Year ending December 31, 2023 | - | 0.00 | |||||||
Year ending December 31, 2023 (Forecast) | - | 0.00 |
Total
Yen 0.00
0.00
3. Forecast of consolidated financial results for the year ending December 31, 2023 (from January 1, 2023 to December 31, 2023)
Percentages indicate year-on-year changes
Net sales | Operating profit | Ordinary profit | Profit attributable to | Earnings per share | ||||||||
owners of parent | ||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen | ||||
Full year | 400 | (10.7) | (1,400) | - | (1,410) | - | (1,390) | - | (44.60) |
1
4. Notes
- Changes in significant subsidiaries during the six months ended June 30, 2023 (changes in specified subsidiaries resulting in the change in scope of consolidation):
- Application of special accounting methods for preparing quarterly consolidated financial statements:
No
No
(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
Changes in accounting policies due to revisions to accounting standards and other regulations: | No |
Changes in accounting policies due to other reasons: | No |
Changes in accounting estimates: | No |
Restatement of prior period financial statements: | No |
(4) Number of issued shares (common shares)
Total number of issued shares at the end of the period (including treasury shares)
As of June 30, 2023 | 31,955,730 | shares | As of December 31, 2022 | 30,871,138 | shares | |
Number of treasury shares at the end of the period | ||||||
As of June 30, 2023 | 285 | shares | As of December 31, 2022 | 100 | shares | |
Average number of shares during the period (cumulative from the beginning of the fiscal year) | ||||||
Six months ended June 30, 2023 | 31,448,528 | shares | Six months ended June 30, 2022 | 29,378,997 | shares |
2
Quarterly consolidated financial statements
Consolidated balance sheets
(Thousands of yen) | ||
As of December 31, 2022 | As of June 30, 2023 | |
Assets | ||
Current assets | ||
Cash and deposits | 2,334,668 | 2,235,105 |
Accounts receivable - trade | 170,755 | 102,911 |
Supplies | 79,211 | 140,920 |
Other | 74,436 | 61,928 |
Total current assets | 2,659,072 | 2,540,866 |
Non-current assets | ||
Property, plant and equipment | 10,105 | 11,236 |
Intangible assets | ||
Contract-related intangible assets | 123,428 | 102,857 |
Other | 1,101 | 763 |
Total intangible assets | 124,529 | 103,620 |
Investments and other assets | 162,668 | 164,813 |
Total non-current assets | 297,303 | 279,670 |
Total assets | 2,956,376 | 2,820,536 |
Liabilities | ||
Current liabilities | ||
Current portion of long-term borrowings | 120,000 | 60,000 |
Accounts payable - other | 64,210 | 124,444 |
Income taxes payable | 11,234 | 10,236 |
Other | 15,762 | 12,457 |
Total current liabilities | 211,207 | 207,138 |
Non-current liabilities | ||
Convertible-bond-type bonds with share acquisition rights | 734,693 | 624,489 |
Long-term borrowings | 113,000 | 144,000 |
Other | 24,000 | 24,000 |
Total non-current liabilities | 871,693 | 792,489 |
Total liabilities | 1,082,900 | 999,628 |
Net assets | ||
Shareholders' equity | ||
Share capital | 714,244 | 815,663 |
Capital surplus | 2,772,484 | 2,873,902 |
Retained earnings | (1,629,961) | (1,877,945) |
Treasury shares | - | (0) |
Total shareholders' equity | 1,856,767 | 1,811,620 |
Accumulated other comprehensive income | ||
Valuation difference on available-for-sale securities | (222) | (31) |
Total accumulated other comprehensive income | (222) | (31) |
Share acquisition rights | 943 | 736 |
Non-controlling interests | 15,987 | 8,583 |
Total net assets | 1,873,475 | 1,820,908 |
Total liabilities and net assets | 2,956,376 | 2,820,536 |
3
Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)
Consolidated statements of income (cumulative)
(Thousands of yen) | ||
Six months ended | Six months ended | |
June 30, 2022 | June 30, 2023 | |
Net sales | 210,034 | 187,710 |
Cost of sales | 13,126 | 14,696 |
Gross profit | 196,908 | 173,014 |
Selling, general and administrative expenses | ||
Research and development expenses | 199,768 | 294,752 |
Other | 129,507 | 136,614 |
Total selling, general and administrative expenses | 329,275 | 431,366 |
Operating loss | (132,367) | (258,352) |
Non-operating income | ||
Interest income | 13 | 6 |
Foreign exchange gains | 32,820 | 6,275 |
Other | 1,008 | 11 |
Total non-operating income | 33,841 | 6,292 |
Non-operating expenses | ||
Interest expenses | 1,710 | 1,225 |
Share issuance costs | - | 1,007 |
Commission expenses | 13,250 | 255 |
Share issuance costs | 4,634 | - |
Other | - | 42 |
Total non-operating expenses | 19,595 | 2,530 |
Ordinary loss | (118,120) | (254,590) |
Loss before income taxes | (118,120) | (254,590) |
Income taxes - current | 797 | 797 |
Total income taxes | 797 | 797 |
Loss | (118,918) | (255,387) |
Loss attributable to non-controlling interests | (8,436) | (7,403) |
Loss attributable to owners of parent | (110,481) | (247,983) |
4
Consolidated statements of comprehensive income (cumulative)
(Thousands of yen) | ||
Six months ended | Six months ended | |
June 30, 2022 | June 30, 2023 | |
Loss | (118,918) | (255,387) |
Other comprehensive income | ||
Valuation difference on available-for-sale securities | (454) | (31) |
Total other comprehensive income | (454) | (31) |
Comprehensive income | (119,372) | (255,419) |
Comprehensive income attributable to | ||
Comprehensive income attributable to owners of parent | (110,936) | (248,015) |
Comprehensive income attributable to non-controlling | (8,436) | (7,403) |
interests | ||
5
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
D.Western Therapeutics Institute Inc. published this content on 10 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 August 2023 07:22:04 UTC.